. * * window.aa needs to exist and be usable by ANY module's script, * however early it runs - main-nav's script, for one, runs near * the top of

91探花

, well before the real search-insights.js * so the download * begins as early as before. Repeat calls share the same downloads, a * failed load is retried on the next call, and the versions / SRI * hashes live only here. * * Algolia Insights is unaffected: window.aa above is still created in * on every page and queues events until search-insights loads. * * window.loadAlgoliaLibs({ priority: 'high' }) (Oct 2026): used by the * /search page, where the first results wait on these libraries. Chrome * gives async scripts low priority, behind images and fonts; this asks * for high instead (fetchpriority). Only the first call for a library * sets its priority - later calls share that download. */ (function (win, doc) { var LIBS = [ { ready: function () { return !!win['algoliasearch/lite']; }, src: 'https://cdn.jsdelivr.net/npm/algoliasearch@5.52.1/dist/lite/builds/browser.umd.js', integrity: 'sha256-I2oYUIvhx1g6l4lTP+yoERbzLIHKzw4AKaBRQPwIeDY=' }, { ready: function () { return !!win.instantsearch; }, src: 'https://cdn.jsdelivr.net/npm/instantsearch.js@4.98.0/dist/instantsearch.production.min.js', integrity: 'sha256-ngmqZk4WBxUw257aMYZayyNBd983INngagv0jI6Ecfs=' } ]; function loadOne(lib, options) { if (lib.ready()) return Promise.resolve(); // One download per library, shared by every caller; reset on // failure so the next call retries just the library that failed. if (lib.pending) return lib.pending; lib.pending = new Promise(function (resolve, reject) { var script = doc.createElement('script'); script.src = lib.src; script.integrity = lib.integrity; script.crossOrigin = 'anonymous'; script.async = true; if (options && options.priority === 'high') script.setAttribute('fetchpriority', 'high'); script.onload = function () { lib.ready() ? resolve() : reject(new Error('Loaded but not available: ' + lib.src)); }; script.onerror = function () { script.remove(); reject(new Error('Could not load ' + lib.src)); }; doc.head.appendChild(script); }); lib.pending.catch(function () { lib.pending = null; }); return lib.pending; } win.loadAlgoliaLibs = function (options) { return Promise.all(LIBS.map(function (lib) { return loadOne(lib, options); })); }; })(window, document); . */ window.hsConversationsSettings = window.hsConversationsSettings || {}; window.hsConversationsSettings.loadImmediately = false; (function (win) { var EVENTS = ['pointerdown', 'keydown', 'touchstart', 'scroll', 'mousemove', 'wheel']; var done = false; /* 19 Oct 2026 - chat widget layout shift (field CLS). Phones fail Core Web Vitals on CLS (p75 ~0.2 site-wide in CrUX for months). Biggest cause found: HubSpot's chat container is fixed to the bottom-right corner and changes size - 100x96 launcher to 282x253 when the welcome message pops up (~5 s after load), and to full screen when a visitor opens the chat. Its top-left corner moves, so Chrome scores it as a layout shift: 0.088 per page view at 360x640 (0.044 at 412x850), on every page. Taps happen inside the chat iframe, so the parent page never sees the input and the open/close shifts count too. Fix: whenever the container's size changes it is made transparent for 400 ms (Chrome doesn't score shifts of invisible elements), then shown again at its new size. Tested on live io1001 at 360x640 in a cookie-less frame: the 0.088 shift no longer appears. The chat itself is unchanged - it just appears 0.4 s later at each resize. Relies on HubSpot's container id; if that changes this does nothing (no error). */ function cloakChatResizes() { var ID = 'hubspot-messages-iframe-container'; function watch(c) { if (c.getAttribute('data-bb-cloak')) return; c.setAttribute('data-bb-cloak', '1'); var last = c.offsetWidth + 'x' + c.offsetHeight, timer = null; new MutationObserver(function () { var size = c.offsetWidth + 'x' + c.offsetHeight; if (size === last) return; last = size; c.style.setProperty('opacity', '0', 'important'); clearTimeout(timer); timer = setTimeout(function () { c.style.removeProperty('opacity'); }, 400); }).observe(c, { attributes: true, attributeFilter: ['style', 'class'], subtree: true, childList: true }); } var found = document.getElementById(ID); if (found) { watch(found); return; } if (!document.body || !('MutationObserver' in win)) return; var mo = new MutationObserver(function () { var c = document.getElementById(ID); if (c) { mo.disconnect(); watch(c); } }); mo.observe(document.body, { childList: true }); setTimeout(function () { mo.disconnect(); }, 30000); } function loadWidget() { var api = win.HubSpotConversations; if (api && api.widget && api.widget.status && api.widget.status().loaded) return; try { cloakChatResizes(); } catch (e) {} if (api && api.widget) api.widget.load(); } function onFirstInteraction() { if (done) return; done = true; EVENTS.forEach(function (type) { win.removeEventListener(type, onFirstInteraction, { passive: true }); }); var start = function () { if (win.HubSpotConversations) loadWidget(); else (win.hsConversationsOnReady = win.hsConversationsOnReady || []).push(loadWidget); }; if ('requestIdleCallback' in win) win.requestIdleCallback(start, { timeout: 1500 }); else setTimeout(start, 200); } EVENTS.forEach(function (type) { win.addEventListener(type, onFirstInteraction, { passive: true }); }); })(window);

91探花

Skip to main content
Home
About us
News
Collaborating with Mekonos to advance non-viral cell engineering

04.05.2023 | Published by Mekonos

Collaborating with Mekonos to advance non-viral cell engineering

Featured Image

New collaboration combines the Mekonos novel ex vivo delivery platform with 91探花鈥檚 unique opti-ox鈩� precision cellular reprogramming technology

SAN FRANCISCO, 4th May 2023 鈥�  a biotech platform company building the future of cell therapies on a chip, has announced a new research collaboration with 91探花.   

The collaboration will test and optimise non-viral delivery of 91探花鈥檚 patented safe harbour gene-targeting approach which is used to inducibly express transcription factor combinations to reprogram human induced pluripotent stem cells (iPSCs) to accelerate the development of human cells for research, drug discovery and next-generation cell therapies. 

"The combination of Mekonos鈥� unique, silicon chip-based delivery platform with 91探花鈥檚 leading cellular reprogramming technologies will enable powerful new levels of precision and efficiency in the engineering of iPSCs. We are excited to partner with the world-class team at 91探花 鈥� leaders in synthetic biology and the engineering of human cells 鈥� and to leverage Mekonos鈥� unique non-viral platform for ex-vivo delivery of reprogramming factors to engineer human cells at unprecedented scale and efficiency."

Jake Lesnik
Jake LesnikMekonos VP of Business Development

Developing this approach as an alternative to viral vector delivery will enable 91探花 to precisely engineer stem cells into any mature, functional human cell type with higher efficiency, speed and control.

"Efficient delivery and targeted integration of genetic payloads will be a critical step in manufacturing clinical grade iPSCs for cell therapies. Together with 91探花鈥檚 cellular reprogramming approach, iPSCs have the potential to enable access to allogeneic cell therapies at an affordable cost and to manufacture them as 鈥榦ff the shelf鈥� products. We are optimistic this collaboration will help unlock new opportunities for efficiency in the iPSC engineering process that further advance our cell therapy development."

91探花_CIRCLEheadshot_July24-Przemek-Obloj-3
Mark KotterCo-founder and CEO, 91探花

Initial results stemming from the research collaboration are expected mid-year. Read more about our opti-ox technology and platform here. 

About Mekonos, Inc.

Mekonos is an enabling technology company transforming synthetic biology and personalized medicine. The company's ex vivo delivery platform merges innovations in semiconductor, microfluidics, and chemistry for controlled and individualized molecular delivery in cells at scale. The company is headquartered in San Francisco, is backed by leading investors in both healthcare and technology, and was named a 2018 Fierce 15 Startup. For more information, please visit their .  

Related pages

About us Coding cells to advance the wellbeing of humanity
Careers See the latest openings
Blog See the latest blogs